Delcath's Revenue Soars 192% YTD on HEPZATO Traction, CHOPIN Trial Boosts Outlook

Ticker: DCTH · Form: 10-Q · Filed: Nov 4, 2025 · CIK: 872912

Sentiment: bullish

Topics: Biotechnology, Oncology, Medical Devices, Clinical Trials, Revenue Growth, Profitability, FDA Approval

TL;DR

**DCTH is finally turning the corner with massive revenue growth and a clear path to expanded indications, making it a compelling buy for growth-oriented investors.**

AI Summary

DELCATH SYSTEMS, INC. (DCTH) reported a significant increase in product revenue, reaching $20.563 million for the three months ended September 30, 2025, up from $11.200 million in the prior year, representing an 83.6% increase. For the nine months ended September 30, 2025, product revenue surged to $64.503 million from $22.105 million in 2024, a 192% increase. The company achieved a net income of $830 thousand for the three months ended September 30, 2025, compared to $1.864 million in the same period of 2024, and a net income of $4.596 million for the nine months ended September 30, 2025, a substantial improvement from a net loss of $22.988 million in 2024. Key business changes include the first commercial use of HEPZATO KIT in January 2024 and the recent positive results from the CHOPIN clinical trial for CHEMOSAT, showing a one-year progression-free survival rate of 54.7% in the combination group versus 15.8% in the PHP group. Risks include the uncertainty of broad adoption of approved products, significant competition, and potential supply chain disruptions due to geopolitical events or raw material shortages. The strategic outlook involves generating further clinical data for CHEMOSAT and HEPZATO as monotherapy or in combination with immunotherapy to support increased adoption and reimbursement, and expanding indications to other cancers like metastatic colorectal cancer and metastatic breast cancer, with Phase 2 trials for both cleared by the FDA.

Why It Matters

This strong revenue growth and return to profitability are critical for investors, signaling successful commercialization of HEPZATO KIT and potential market penetration. The positive CHOPIN trial results for CHEMOSAT, especially the 54.7% one-year progression-free survival rate in the combination group, could significantly enhance Delcath's competitive position against other liver cancer treatments, potentially attracting more patients and increasing physician adoption. For employees, this financial stability and clinical progress suggest job security and growth opportunities. Customers stand to benefit from expanded treatment options for complex liver cancers, particularly with the potential for combination therapies. The broader market could see increased innovation in interventional oncology, pushing competitors to accelerate their own R&D efforts.

Risk Assessment

Risk Level: medium — The company faces medium risk due to the uncertainty of broad adoption of its approved products by physicians and consumers, as stated in the 'Risks and Uncertainties' section. Additionally, significant competition in the biopharmaceutical industry and potential supply chain disruptions, which could lead to inventory write-offs and increased manufacturing costs, pose ongoing challenges to sustained profitability.

Analyst Insight

Investors should consider initiating or increasing positions in DCTH, given the substantial revenue growth and the positive clinical trial results for CHEMOSAT, which could drive future market expansion and reimbursement. Monitor the progress of the Phase 2 trials for metastatic colorectal cancer and metastatic breast cancer, as successful outcomes could significantly broaden the company's addressable market and valuation.

Financial Highlights

debt To Equity
N/A
revenue
$64.503M
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
$4.596M
eps
N/A
gross Margin
N/A
cash Position
$41.813M
revenue Growth
+192%

Revenue Breakdown

SegmentRevenueGrowth
Product Revenue$64.503M+192%
Product Revenue (Q3)$20.563M+83.6%

Key Numbers

Key Players & Entities

FAQ

What were Delcath Systems' (DCTH) key financial results for the nine months ended September 30, 2025?

For the nine months ended September 30, 2025, Delcath Systems reported product revenue of $64.503 million, a 192% increase from $22.105 million in the prior year. The company achieved a net income of $4.596 million, a significant improvement from a net loss of $22.988 million in the same period of 2024.

How has the HEPZATO KIT impacted Delcath Systems' (DCTH) performance?

The HEPZATO KIT, approved by the FDA on August 14, 2023, and commercially launched in January 2024, has been a primary driver of Delcath Systems' revenue growth. Product revenue for the three months ended September 30, 2025, increased to $20.563 million from $11.200 million, largely due to its commercial use.

What are the significant clinical trial updates for Delcath Systems (DCTH)?

Delcath Systems announced positive results from the CHOPIN clinical trial on October 18, 2025, showing a one-year progression-free survival rate of 54.7% for CHEMOSAT combined with immune checkpoint inhibitors, compared to 15.8% for CHEMOSAT alone. Additionally, the FDA cleared IND applications for Phase 2 trials of HEPZATO in liver-dominant metastatic colorectal cancer (December 2024) and metastatic breast cancer (April 28, 2025).

What are the main risks Delcath Systems (DCTH) faces?

Delcath Systems faces risks including the uncertainty of broad adoption of its approved products by physicians and consumers, significant competition in the biopharmaceutical industry, and potential supply chain disruptions due to geopolitical events, raw material shortages, or other factors, which could increase manufacturing costs or lead to revenue loss.

How much cash and cash equivalents does Delcath Systems (DCTH) have?

As of September 30, 2025, Delcath Systems reported cash and cash equivalents of $41.813 million, an increase from $32.412 million as of December 31, 2024. This reflects a net increase of $9.401 million in total cash during the nine-month period.

What is Delcath Systems' (DCTH) strategy for expanding its product indications?

Delcath Systems is pursuing clinical development programs to generate data for CHEMOSAT and HEPZATO as monotherapy or in combination with immunotherapy. The company believes HEPZATO has potential to treat other cancers in the liver, such as metastatic colorectal cancer and metastatic breast cancer, and has initiated Phase 2 trials for these indications.

What was Delcath Systems' (DCTH) gross profit for the nine months ended September 30, 2025?

Delcath Systems' gross profit for the nine months ended September 30, 2025, was $55.716 million. This represents a substantial increase from $18.043 million in the same period of 2024, driven by higher product revenue.

What is the status of Delcath Systems' (DCTH) European operations?

In Europe, CHEMOSAT received MDR certification on February 28, 2022. In June 2025, CHEMOSAT was approved for reimbursement for two years in the Vastra Gotaland Region in Sweden. The company is also conducting clinical studies in the European Union and United Kingdom for Melphalan for Injection/Hepatic Delivery System in patients with refractory metastatic colorectal cancer.

How many shares of common stock does Delcath Systems (DCTH) have outstanding?

As of October 27, 2025, Delcath Systems had 35,313,718 shares of its common stock, $0.01 par value, outstanding. This figure reflects the issuance of common stock through employee stock purchase plans, warrant exercises, and stock option exercises during the period.

What is the significance of the CHOPIN trial results for Delcath Systems (DCTH) investors?

The CHOPIN trial results are significant for investors as they demonstrate superior efficacy for CHEMOSAT when combined with immune checkpoint inhibitors, with a median OS of 23.1 months versus 19.6 months and an ORR of 76.3% versus 39.5%. These strong clinical outcomes could lead to increased adoption, expanded reimbursement, and a stronger competitive position for Delcath's products, potentially driving future stock performance.

Risk Factors

Industry Context

Delcath Systems operates in the oncology therapeutics market, focusing on novel drug-device combination therapies. The industry is characterized by high R&D costs, long development cycles, and intense competition from both large pharmaceutical companies and smaller biotech firms. There is a growing trend towards personalized medicine and combination therapies to improve patient outcomes, which aligns with Delcath's strategic focus.

Regulatory Implications

Delcath's success is heavily dependent on regulatory approvals and favorable reimbursement decisions from bodies like the FDA and CMS. Positive clinical trial data for CHEMOSAT and HEPZATO KIT are crucial for expanding indications and securing market access. Any delays or adverse decisions could significantly impact the company's growth trajectory.

What Investors Should Do

  1. Monitor clinical trial progress and FDA submissions for CHEMOSAT and HEPZATO.
  2. Track product sales and market adoption rates for HEPZATO KIT.
  3. Assess competitive landscape and potential new entrants.
  4. Evaluate the company's cash burn and financing activities.

Key Dates

Glossary

HEPZATO KIT
A therapeutic product developed by Delcath Systems, Inc. (Key product contributing to the significant increase in product revenue.)
CHEMOSAT
Another therapeutic product/system developed by Delcath Systems, Inc. (Positive clinical trial results for CHEMOSAT are driving strategic outlook and potential market expansion.)
CHOPIN clinical trial
A clinical trial evaluating the efficacy of CHEMOSAT. (Recent positive results (54.7% PFS) are a key driver of investor confidence and future growth prospects.)
Progression-Free Survival (PFS)
The length of time during and after treatment that a disease does not get worse. (A key metric from the CHOPIN trial showing significant improvement in the combination group (54.7% vs. 15.8%).)
PHP
Likely refers to a control or comparator arm in the CHOPIN trial, possibly 'peritoneal hyperthermia' or a similar standard of care. (Used as a benchmark in the CHOPIN trial to demonstrate the efficacy of CHEMOSAT.)
Overall Response Rate (ORR)
The percentage of patients in a clinical trial whose cancer shrinks or disappears after treatment. (High ORR (76.3% vs. 39.5%) in the CHOPIN trial indicates strong efficacy of the CHEMOSAT combination therapy.)
Overall Survival (OS)
The length of time patients live after starting treatment for a disease. (Median OS of 23.1 months in the CHOPIN combination group shows a significant survival benefit compared to the PHP group (19.6 months).)

Year-Over-Year Comparison

Delcath Systems has demonstrated substantial year-over-year improvement. Product revenue for the nine months ended September 30, 2025, surged by 192% to $64.503 million, a significant leap from $22.105 million in 2024. This revenue growth has translated into a dramatic swing from a net loss of $22.988 million to a net income of $4.596 million for the same period. Cash and cash equivalents have also seen a healthy increase, rising to $41.813 million from $32.412 million at year-end 2024, indicating improved financial health and operational efficiency, with net cash provided by operating activities improving from a significant outflow to a positive inflow.

Filing Stats: 4,732 words · 19 min read · ~16 pages · Grade level 17.6 · Accepted 2025-11-04 09:04:41

Key Financial Figures

Filing Documents

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements Unaudited Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income and Loss for the three and nine months ended September 30, 2025 and 2024 4 Unaudited Condensed Consolidated Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024 5 Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 7 Notes to the Unaudited Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29

—OTHER INFORMATION

PART II—OTHER INFORMATION 30 Item 1 .

Legal Proceedings

Legal Proceedings 30 Item 1A.

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 32

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 32

Mine Safety Disclosure

Item 4. Mine Safety Disclosure 32

Other Information

Item 5. Other Information 33 Item 6. Exhibits 34

SIGNATURES

SIGNATURES 35 2 Table of Contents DELCATH SYSTEMS, INC. Condensed Consolidated Balance Sheets (Unaudited) (in thousands, except share and per share data) September 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 41,813 $ 32,412 Short-term investments 47,099 20,821 Accounts receivable 13,751 10,890 Inventories 10,745 6,933 Prepaid expenses and other current assets 7,207 2,704 Total current assets 120,615 73,760 Property, plant and equipment, net 2,715 1,790 Right-of-use assets 965 1,039 Total assets $ 124,295 $ 76,589 Liabilities and Stockholders' Equity Current liabilities Accounts payable $ 2,133 $ 961 Accrued expenses 5,768 5,078 Lease liabilities, current 110 105 Total current liabilities 8,011 6,144 Lease liabilities, non-current 855 933 Other liabilities, non-current 582 766 Total liabilities $ 9,448 $ 7,843 Commitments and contingencies (see Note 12) Stockholders' equity Preferred stock, $ 0.01 par value; 10,000,000 shares authorized; 14,192 and 14,192 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively — — Common stock, $ 0.01 par value; 80,000,000 shares authorized; 35,308,939 shares and 33,061,002 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 353 331 Additional paid-in capital 640,571 599,881 Accumulated deficit ( 526,952 ) ( 531,548 ) Accumulated other comprehensive income 875 82 Total stockholders' equity 114,847 68,746 Total liabilities and stockholders' equity $ 124,295 $ 76,589 See accompanying Notes to Unaudited Condensed Consolidated Financial Statements. 3 Table of Contents DELCATH SYSTEMS, INC. Condensed Consolidated Statements of Operations and Comprehensive Income and Loss (Unaudited) (in thousands, except share and per share data) Three months ended September 30, Nine months ended September 30, 2025 2024 2025 2024 Product revenue $ 20,563 $ 11,200 $ 64,503 $ 22,105 Cost of goods sold

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing